Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment

American Journal of Gastroenterology

Volumn 106, Issue 10, 2011, Pages 1766-1773

  Fung, James ^a   Lai, Ching Lung ^a   Young, John ^a   Wong, Danny Ka Ho ^a   Yuen, John ^a   Seto, Wai Kay ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CORRELATION ANALYSIS; DRUG ACTIVITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROCONVERSION; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 80053894414     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.253     Document Type: Article

References (27)

1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
2. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-803. (Pubitemid 44166589)
3. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91. (Pubitemid 32928004)
4. Reijnders JG, Leemans WF, Hansen BE, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009; 16: 113-20.
5. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36. (Pubitemid 41096641)
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 3: 263-83.
8. European Association For The Study Of The Liver. (EASL) clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
9. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62. (Pubitemid 44118844)
10. Janssen HL, Kerhof-Los CJ, Heijtink RA, et al. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251-7. (Pubitemid 24122302)
11. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8. (Pubitemid 350181604)
12. Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-23.
13. Tangkijvanich P, Komolmit P, Mahachai V, et al. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res 2010; 40: 269-77.
14. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAgnegative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
15. Wursthorn K, Jung M, Manns M, et al. Different kinetics of serum HBsAg decline in HBeAg-positive vs HBeAg-negative patients during 3 years of telbivudine treatment in chronic hepatitis B. Hepatology 2009; 50: 536A.
16. Desalegn A, Jiang Y, Cai Y, et al. Serum HBsAg and HBV DNA among HBeAg positive and negative chronic hepatitis B patients during adefovir dipivoxil therapy. Hepatology 2009; 50: 541-542A.
17. Van Bommel F, Bock F, Hensel-Wiegel K, et al. Kinetics of HBsAg levels in patients with chronic hepatitis B virus (HBV) infection during up to 4 years of treatment with acyclic nucleotide analogues. Hepatology 2009; 50: 522A.
18. Chen J, Wang Z, Guo Y, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 2009; 81: 88-91.
19. Jung YK, Kim JH, Lee YS, et al. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigenpositive patients receiving entecavir. J Clin Gastroenterol 2010; 44: 653-7.
20. Bonino F, Brunetto MR, Colombatto P, et al. Use of the Elecsys ® HBsAg II assay for simple and accurate quantification of HBsAg levels in sera of patients infected with HBV. Hepatol Int 2009; 3: 108.
21. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Vol 2011; 50: 292-6.
22. Martinot-Peignoux M, Lada O, Mackiewicz V, et al. Elecsys HBsAg II assay: an accurate technique for the quantification of serum HBsAg and prediction of treatment outcome. Hepatology 2010; 52 (4 suppl): 996A.
23. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
24. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
25. Takkenberg B, Zaaijer H, Niet A, et al. High levels of HBsAg and HBV DNA during treatment predict failure for HBeAg seroconversion in HBeAg positive chronic hepatitis B patients treated with peginterferon alfa-2a (Pegasys) and adefovir (Hepsera); an interim analysis. Hepatology 2009; 50: 541A.
26. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55: 61-8.
27. Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11: 909-16. (Pubitemid 44736182)